PYPD Share Price Performance
US$4.39
1.68 (61.99%)
64.2% undervalued intrinsic discount
US$12.25
Fair Value
Price US$4.39
AnalystConsensusTarget US$12.25
AnalystHighTarget US$14.00
Fair ValueUS$12.25
Share Pricen/a
PolyPid Ltd. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
PYPD Community Narratives
AN
Fair Value US$12.25 64.2% undervalued intrinsic discount
Regulatory Tailwinds And Extended Release Platform Will Shape A Stronger Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$14 68.6% undervalued intrinsic discount
Long Acting Drug Delivery And Metabolic Health Pipeline Will Transform Future Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regulatory Tailwinds And Extended Release Platform Will Shape A Stronger Long Term Outlook
Catalysts About PolyPid PolyPid is a biopharmaceutical company focused on extended release drug delivery products such as D-PLEX100 for prevention of surgical site infections and longer acting metabolic therapies using its Kynatrix technology. What are the underlying business or industry changes driving this perspective?Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$12.25
64.2% undervalued intrinsic discount
Fair Value
Profit Margin
7.27%
Future PE
61.91x
Price in 2029
US$0
Long Acting Drug Delivery And Metabolic Health Pipeline Will Transform Future Prospects
Catalysts About PolyPid PolyPid is a clinical stage biopharmaceutical company focused on long acting drug delivery products such as D PLEX100 for prevention of surgical site infections and a GLP 1 receptor agonist program for metabolic disease. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$14
68.6% undervalued intrinsic discount
Fair Value
Profit Margin
7.29%
Future PE
66.64x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Regulatory Tailwinds And Extended Release Platform Will Shape A Stronger Long Term Outlook
Fair Value: US$12.25 64.2% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Long Acting Drug Delivery And Metabolic Health Pipeline Will Transform Future Prospects
Fair Value: US$14 68.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
PolyPid Ltd. Key Details
About PYPD
- Founded
- 2008
- Employees
- 72
- CEO
- WebsiteView website
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
